BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 8258394)

  • 1. Interferon alfa-2a in the treatment of exudative age-related macular degeneration.
    Lewis ML; Davis J; Chuang E
    Graefes Arch Clin Exp Ophthalmol; 1993 Nov; 231(11):615-8. PubMed ID: 8258394
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical experience with interferon alfa-2a for exudative age-related macular degeneration.
    Kirkpatrick JN; Dick AD; Forrester JV
    Br J Ophthalmol; 1993 Dec; 77(12):766-70. PubMed ID: 7509185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interferon alpha-2a in the treatment of exudative senile macular degeneration.
    Jaakkola A; Anttila PM; Immonen I
    Acta Ophthalmol (Copenh); 1994 Oct; 72(5):545-9. PubMed ID: 7534027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interferon alpha-2a for subfoveal neovascularization in age-related macular degeneration.
    Poliner LS; Tornambe PE; Michelson PE; Heitzmann JG
    Ophthalmology; 1993 Sep; 100(9):1417-24. PubMed ID: 8371932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of choroidal neovascularisation in age-related macular degeneration with interferon alfa-2a and alfa-2b.
    Gillies MC; Sarks JP; Beaumont PE; Hunyor AB; McKay D; Kearns M; McClusky PJ; Sarks SH
    Br J Ophthalmol; 1993 Dec; 77(12):759-65. PubMed ID: 7509184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interferon alfa-2a is ineffective for patients with choroidal neovascularization secondary to age-related macular degeneration. Results of a prospective randomized placebo-controlled clinical trial. Pharmacological Therapy for Macular Degeneration Study Group.
    Arch Ophthalmol; 1997 Jul; 115(7):865-72. PubMed ID: 9230826
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interferon alpha-2a treatment of patients with subfoveal neovascular macular degeneration. A pilot investigation.
    Engler CB; Sander B; Koefoed P; Larsen M; Vinding T; Lund-Andersen H
    Acta Ophthalmol (Copenh); 1993 Feb; 71(1):27-31. PubMed ID: 7682747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of choroidal neovascularization in age-related macular degeneration with interferon alpha-2a: a short term, nonrandomized pilot study.
    Thoelen A; Menozzi M; Huber C; Messmer E
    Ger J Ophthalmol; 1995 May; 4(3):137-43. PubMed ID: 7545047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retinal pigment epithelium and choroid translocation in patients with exudative age-related macular degeneration: long-term results.
    Maaijwee K; Heimann H; Missotten T; Mulder P; Joussen A; van Meurs J
    Graefes Arch Clin Exp Ophthalmol; 2007 Nov; 245(11):1681-9. PubMed ID: 17562066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A retained catheter for retrobulbar administration of interferon for age-related macular degeneration.
    Lincoff H; Kreissig I; Gelisken F; Stanga P
    Dev Ophthalmol; 1997; 29():69-77. PubMed ID: 9413697
    [No Abstract]   [Full Text] [Related]  

  • 11. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization--verteporfin in photodynamic therapy report 2.
    Verteporfin In Photodynamic Therapy Study Group
    Am J Ophthalmol; 2001 May; 131(5):541-60. PubMed ID: 11336929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of a macular buckle in the treatment of exudative age-related macular degeneration.
    Peyman GA; Conway MD; Recasens MA; Peralta E; Kertes PJ; Greve MD; El-Dessouky ES
    Ophthalmic Surg Lasers; 1999; 30(8):619-30. PubMed ID: 10507564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interferon alfa-2a in the treatment of subfoveal choroidal neovascularization.
    Thomas MA; Ibanez HE
    Am J Ophthalmol; 1993 May; 115(5):563-8. PubMed ID: 7683842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natural course in fellow eyes of patients with unilateral age-related exudative maculopathy. A fluorescein angiographic 4-year follow-up of 45 patients.
    Baun O; Vinding T; Krogh E
    Acta Ophthalmol (Copenh); 1993 Jun; 71(3):398-401. PubMed ID: 8362642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferon alfa-2a modifies the course of subfoveal and juxtafoveal choroidal neovascularisation.
    Engler C; Sander B; Villumsen J; Lund-Andersen H
    Br J Ophthalmol; 1994 Oct; 78(10):749-53. PubMed ID: 7528534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treatment of age-associated macular degeneration with interferon-alfa-2a].
    Thölen A; Kain H; Messmer E
    Ophthalmologe; 1993 Jun; 90(3):279-82. PubMed ID: 8334332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of a single treatment in a phase 1 and 2 study.
    Miller JW; Schmidt-Erfurth U; Sickenberg M; Pournaras CJ; Laqua H; Barbazetto I; Zografos L; Piguet B; Donati G; Lane AM; Birngruber R; van den Berg H; Strong A; Manjuris U; Gray T; Fsadni M; Bressler NM; Gragoudas ES
    Arch Ophthalmol; 1999 Sep; 117(9):1161-73. PubMed ID: 10496388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group.
    Arch Ophthalmol; 1999 Oct; 117(10):1329-45. PubMed ID: 10532441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The treatment of choroidal neovascular membranes by alpha interferon. An efficacy and toxicity study.
    Chan CK; Kempin SJ; Noble SK; Palmer GA
    Ophthalmology; 1994 Feb; 101(2):289-300. PubMed ID: 7509472
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of retreatments in a phase 1 and 2 study.
    Schmidt-Erfurth U; Miller JW; Sickenberg M; Laqua H; Barbazetto I; Gragoudas ES; Zografos L; Piguet B; Pournaras CJ; Donati G; Lane AM; Birngruber R; van den Berg H; Strong HA; Manjuris U; Gray T; Fsadni M; Bressler NM
    Arch Ophthalmol; 1999 Sep; 117(9):1177-87. PubMed ID: 10496389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.